

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/656,356 Confirmation No.: 7827
Applicant : HANASH et al.
Filed : September 5, 2003
TC/A.U. : 1642
Examiner : Fetterolf, Brandon J
Docket No. : 108140.00022
Customer No. : 38485
For : ANNEXIN PROTEINS AND AUTOANTIBODIES AS SERUM
MARKERS FOR CANCER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date: January 5, 2007

INFORMATION DISCLOSURE STATEMENT


Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application.

Identification of the listed documents is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application. If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Applicants believe that there is no fee required for this submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 01-2300 referencing Attorney Docket No. 108140.00022.

Respectfully submitted,

A handwritten signature in cursive script, reading "Rochelle K. Seide", written over a horizontal line.

Rochelle K. Seide, Ph.D.
Registration No. 32,300
ARENT FOX PLLC
1675 Broadway
New York, NY 10019
Tel. No. (212) 484-3945
Fax No. (212) 484-3990
Customer No. 38485

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 108140.00022	SERIAL NO. 10/656,356
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT HANASH et al.	
		FILING DATE September 5, 2006	GROUP 1642

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
						YES	NO	PART.

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	Gilewski, T. et al., Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial, 2000, Vol. 98 :3270-3275
	Sharma, R.M. et al., Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	